Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

NCT00316953 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Accelerated Phase Chronic Myelogenous Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Childhood Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Meningeal Chronic Myelogenous Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Relapsing Chronic Myelogenous Leukemia
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG: dasatinib
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)